A potential link between endothelial function, cardiovascular risk, and metabolic syndrome in patients with Non-alcoholic fatty liver disease

Creative Commons License

Arslan M. S., Turhan S., Dinçer İ., Mizrak D., Çorapçıoğlu D., İdilman R.

DIABETOLOGY & METABOLIC SYNDROME, cilt.6, 2014 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 6
  • Basım Tarihi: 2014
  • Doi Numarası: 10.1186/1758-5996-6-109
  • Dergi Adı: DIABETOLOGY & METABOLIC SYNDROME
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Anahtar Kelimeler: Non-alcoholic fatty liver disease, Metabolic syndrome, Asymmetric dimethylarginine, Endothelial function, Cardiovascular risk, STEATOHEPATITIS, DYSFUNCTION, DIMETHYLARGININE, PROFILE
  • Ankara Üniversitesi Adresli: Evet

Özet

Background: Asymmetric dimethylarginine (ADMA) is an endogenous competitive inhibitor of nitric oxide (NO) synthetase. Elevated ADMA reduces NO formation and is associated with endothelial dysfunction. The aims of this study were to evaluate endothelial function and the cardiovascular risk (CVR) profile in patients with non-alcoholic fatty liver disease (NAFLD), and to determine whether or not an association with metabolic syndrome (MS) increases these parameters.